# Aggrenox Prevention of Access Stenosis

> **NCT00067119** · PHASE3 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 649 (actual)

## Conditions studied

- Kidney Failure

## Interventions

- **DRUG:** Aggrenox
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00067119
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01-01
- **Primary completion:** 2008-01-31
- **Final completion:** 2008-01-31
- **Target enrollment:** 649 (ACTUAL)
- **Last updated:** 2017-09-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00067119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00067119, "Aggrenox Prevention of Access Stenosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00067119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*